Project Grant R01DA059660
- This $619,477 federal Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports research to investigate the impact of electronic cigarette (e-cigarette) exposure, both direct and in-utero, on vascular function and cognitive decline. The research, conducted by the West Virginia University Research Corporation, aims to establish the dose-dependent effects of e-cigarette exposure on vascular dysfunction and...
- This Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, will fund research to examine the effects of nicotine from e-cigarettes on the development of abdominal aortic aneurysm (AAA) and the potential for transgenerational epigenetic impacts. The $355,000 award to the Palo Alto Veterans Institute for Research (Pavir) will support in vitro and in vivo studies to investigate how nicotine and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $306,530.00 to Spinhance LLC to build, qualify, and evaluate the clinical feasibility of a novel cardiopulmonary imaging device. The device is designed for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129 (HPX), which was recently approved by the FDA. The project aims to develop an MRI-compatible, piston-based...
- This federal Project Grant award of $619,175 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports a Type 1 hybrid effectiveness-implementation trial to evaluate a novel harm reduction approach for oncology outpatients who smoke but refuse traditional tobacco treatment. The study will directly compare rates of switching from cigarettes to e-cigarettes against standard care, while also assessing key barriers and facilitators to implementation. The...
- This $317,000 Project Grant was awarded by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), to The Research Foundation for the State University of New York (RFSUNY), doing business as Stony Brook University. The grant aims to establish a screening system and identify histone modulation enzymes critical for e-cigarette-promoted oncogenes and pro-inflammatory genes, as well as to establish an...
- This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
- This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will develop new pulmonary magnetic resonance imaging (MRI) methods on a novel 0.55 Tesla scanner. The $659,644 project, running from September 2025 to June 2029, will focus on improving the spatial resolution and image contrast of structural lung proton MRI, as well as developing methodology for hyperpolarized xenon imaging at this...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $687,995.00 to Yale University to conduct a randomized clinical trial investigating the efficacy of varenicline (Chantix) for cessation of electronic cigarette (e-cigarette) use in adults. The study aims to test the hypothesis that varenicline is an effective intervention for helping e-cigarette users quit, given the addictive nature of nicotine in e-cigarettes and...
- This $723,676 federal Project Grant award was provided by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to Wake Forest University Health Sciences (WFUHS) to conduct research on the long-term effects of electronic cigarettes on brain health. The research project aims to investigate the comparative impacts of smoking cessation versus switching from traditional cigarettes to e-cigarettes on measures such as gray matter volume, white matter...
- The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...
DISSOLVED PHASE HYPERPOLARIZED XENON-129 MRI: A NOVEL BIOMARKER TO QUANTIFY PULMONARY PATHOLOGY IN YOUNG HEALTHY E-CIGARETTE USERS - PROJECT SUMMARY OVER THE PAST TEN YEARS, ELECTRONIC CIGARETTES (E-CIGARETTES) HAVE BEEN COMMERCIALIZED AS A "LESS HARMFUL" ALTERNATIVE TO TRADITIONAL CIGARETTES. PRECLINICAL MODELS SHOW THAT E-CIGARETTES CAUSE PULMONARY EPITHELIAL, ENDOTHELIAL, AND VASCULAR DYSFUNCTION SIMILAR TO HUMAN COPD. E-CIGARETTE USE HAS ALSO BEEN ASSOCIATED WITH CARDIAC AND PULMONARY DISEASES, INCLUDING SEVERE RESPIRATORY FAILURE. HOWEVER, WE STILL DO NOT CLEARLY UNDERSTAND HOW E-CIGARETTE USES IMPACTS LUNG HEALTH IN THE EARLY DAYS OF USE. THEREFORE, THERE IS AN URGENT NEED TO ESTABLISH THE HEALTH IMPACT OF E-CIGARETTES ON HUMAN LUNGS. CONVENTIONAL DIAGNOSTIC TOOLS SUCH AS PULMONARY FUNCTION TESTS (PFT) AND MULTI-DETECTOR COMPUTED TOMOGRAPHY (MDCT) ARE LIMITED IN DETECTING SUBTLE BUT POTENTIALLY SIGNIFICANT EARLY PATHOLOGIES FROM E-CIGARETTE USE. TO ADDRESS THIS SHORTCOMING, WE PROPOSE TO USE 3D HYPERPOLARIZED XENON-129 MRI (HXEMRI) AS A NEW IMAGING BIOMARKER. OUR GROUP HAS OPTIMIZED THE HXEMRI TECHNIQUE TO QUANTIFY THE REGIONAL PHYSIOLOGY OF PULMONARY MICROCOMPARTMENTS (AIRWAY, INTERSTITIAL TISSUES, AND CAPILLARY VASCULATURE) WITH HIGH RESOLUTION AND SENSITIVITY. OUR HXEMRI PILOT STUDY DEMONSTRATED THAT HEALTHY YOUNG E-CIGARETTE USERS WITH NORMAL PFT HAD DYSREGULATED GAS EXCHANGE IN THE INTERSTITIAL TISSUE AND PULMONARY CAPILLARY COMPARTMENTS COMPARED TO AGE-MATCHED CONTROLS. BASED ON THESE PRELIMINARY DATA, WE HYPOTHESIZE THAT QUANTITATIVE HXEMRI SIGNATURES CAN DETECT CLINICALLY RELEVANT EARLY PHYSIOLOGIC CHANGES IN THE LUNGS OF HEALTHY YOUNG E-CIGARETTE USERS. WE SPECULATE THAT A CARDIOPULMONARY EXERCISE TEST (CPET) WILL EXACERBATE THESE DYSREGULATED LUNG FUNCTIONS AND LIMIT HEALTHY YOUNG E-CIGARETTE USERS' EXERCISE CAPACITY BY REDUCING THEIR OXYGEN UPTAKE. THEREFORE, WE HYPOTHESIZE THAT THE CPET, A CLINICAL DIAGNOSTIC STANDARD, WILL CORROBORATE HXEMRI SIGNATURES. TO THE BEST OF OUR KNOWLEDGE, THIS IS THE FIRST TIME ANY NON-INVASIVE TECHNIQUE HAS REVEALED DYSFUNCTIONAL GAS EXCHANGE CAPACITY IN HEALTHY YOUNG E-CIGARETTE USERS WITH NORMAL PFT. OUR TWO AIMS ARE: (1). AIM 1: DETERMINE THE IMPACT OF E-CIGARETTE USE ON PULMONARY GAS EXCHANGE CAPACITY IN INTERSTITIAL TISSUES AND CAPILLARIES USING HXEMRI, AND CORROBORATE THE HXEMRI SIGNATURES WITH THE CPET FOR 40 YOUNG ADULTS WITH E- CIGARETTE USE AT AN INITIAL VISIT (V1) AND A FOLLOW-UP VISIT 12-MONTHS LATER (V2), COMPARED TO 40 AGE-MATCHED HEALTHY CONTROL SUBJECTS WITHOUT E-CIGARETTE USE AS CONTROLS; AND (2). AIM 2: DETERMINE THE ACUTE EFFECTS OF E- CIGARETTES ON PULMONARY GAS EXCHANGE CAPACITY IN INTERSTITIAL TISSUES AND CAPILLARIES AMONG THE E-CIGARETTE USERS FROM AIM 1 BY HXEMRI AT BASELINE AND AFTER BEING PERTURBED BY A DOSE OF E-CIGARETTES DURING THE V1 AND V2 EVALUATIONS. THE RESULT OF OUR PROPOSAL IS ANTICIPATED TO YIELD A COMPREHENSIVE UNDERSTANDING OF THE HEALTH IMPACT OF E-CIGARETTE USE AND BRING FORTH GAS EXCHANGE SIGNATURES OF HXEMRI AS A NEW DIAGNOSTIC TOOL TO ASSESS THESE PATIENTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $739.3k | 4/22/25 | ||
| Not listed | $0 | 11/22/24 | ||
| Not listed | $0 | 11/22/24 | ||
| Not listed | $754.4k | 7/3/24 | ||
| Not listed | $754.4k | 7/3/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
GR105232SUB00001348S | George Mason University | Project Grant R01DA059660 | $85.8k | 4/8/25 | |
GR105231SUB00001347S | Beckman Research Institute Of The City Of Hope | Project Grant R01DA059660 | $31.7k | 3/10/25 |